pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 16·1 min read
save

Human Cell Atlas leadership ties to 10x Genomics spark conflict-of-interest concerns

Jun 16, 2026·read at STAT ↗Negative

The International Human Cell Atlas Consortium is marking its 10-year anniversary with a meeting in Boston that brings together academic and industry leaders.

Attention has turned to one of the project’s leaders because of a personal connection to 10x Genomics, a company that supplies single-cell RNA sequencing tools used by the Atlas.

Observers say the relationship could create a conflict of interest, especially as the Atlas prepares to release its first draft of cell-type maps later this year, a product that could benefit 10x Genomics commercially.

The issue highlights broader questions about how large biomedical initiatives manage ties to commercial vendors while maintaining scientific independence.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questions”

read at STAT ↗
599 words · retrieved Jun 16
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GENENTECHTakara Bio IncWM TECHNOLOGY, INC.
drugs
Obesity
topics
Obesity

related stories

  • Sep 28Roche drops muscle-sparing obesity antibody after flunked interim analysisFierce Biotech
  • Sep 25ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plansFierce Biotech
  • Sep 24Roche inks up to $2B deal with Atavistik for new cardiometabolic drugsBioSpace
  • Aug 28Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioBioSpace
  • Aug 28Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical dataFierce Biotech